Ignite Creation Date:
2024-05-06 @ 3:45 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04747002
Status:
UNKNOWN
Last Update Posted:
2021-03-03
First Post:
2021-02-05
Brief Title:
Investigator-initiated Clinical Trial Phase II of Cancer Vaccine Dainippon Sumitomo PhamaDSP-7888 for Acute Myeloid Leukemia Patients
Sponsor:
Osaka University
Organization:
Osaka University
Study Overview
Official Title:
Investigator-initiated Clinical Trial Phase II of Cancer Vaccine DSP-7888 for Acute Myeloid Leukemia Patients
Status:
UNKNOWN
Status Verified Date:
2021-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an investigator-initiated clinical trial Phase II using DSP-7888 for acute myeloid leukemia patients with 1st hematological complete remission CR DSP-7888 is a novel cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize Wilms Tumor Gene 1 WT1 peptides
Detailed Description:
This study is an investigator-initiated clinical trial Phase II using DSP-7888 for acute myeloid leukemia patients with 1st hematological CR DSP-7888 is a novel cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides Primary endpoint is relapse-free survival and 2nd endpoint is hematological relapse-free survival overall survival and adverse event
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None